Prognostic Value of Interferon Gamma Release Assays in Predicting Active Tuberculosis Among Individuals With, or at Risk of, Latent Tuberculosis Infection

Launched by PUBLIC HEALTH ENGLAND · Jul 13, 2010

Keywords

ClinConnect Summary

DESIGN: Prospective cohort study of individuals (\> or = 16 yrs) who are: (a) close contacts of TB cases or (b) new entrants from high incidence countries (\>40/100000). SETTING: London TB clinics. NE London TB Network Primary Care Practices. All study sites will be coordinated from the HPA Centre for Infections.

HEALTH TECHNOLOGIES (LTBI MEASURES):Participants will be tested by Mantoux TST and two IGRA tests(Quantiferon-Gold In Tube ELISA) and ELISpot assay (same as Tspot.TB). A 25ml blood specimen will be collected with the residuum, after IGRA testing, full blood count and repetition of...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Contacts of all active TB (pulmonary and extrapulmonary) patients. (Contacts will include all individuals with a cumulative duration of exposure of greater than eight hours to the relevant index case in a confined space during the period of infectiousness (prior to initiation of treatment) who attend designated clinics.
• • New entrants from high incidence countries (incidence of TB of \>40/100000) who attend designated clinics
• Exclusion Criteria:
• • Patients who are unable to give informed consent
• • Children under 16 years of age
• • Individuals found to have active TB at the time of screening